Clinical Report: Transformative Treatment Approaches for Initially Unresectable Intrahepatic Cholangiocarcinoma

Background

Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive cancer with increasing incidence and poor prognosis, particularly for patients diagnosed at advanced stages. The standard first-line treatment, gemcitabine and cisplatin, has limited effectiveness.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

• The patient initially presented with unresectable ICC due to extensive tumor infiltration and inadequate future liver remnant.
• Conversion therapy included percutaneous portal vein embolization (PVE), surufatinib, sintilimab, and FOLFOX chemotherapy.
• Post-treatment imaging showed significant tumor reduction and increased future liver remnant volume.
• The patient successfully underwent radical liver resection and had a smooth recovery.
• At 28 months follow-up, the patient remained disease-free with no signs of recurrence.

Clinical Implications

The case illustrates the potential of multimodal conversion therapy in managing initially unresectable ICC, combining anti-tumor effectiveness with clinical practicality. This approach may serve as a model for future treatment strategies in similar patient populations.

Conclusion

The successful application of conversion therapy in this case suggests a promising direction for treating advanced ICC. Further studies are warranted to validate these findings in larger cohorts.

Related Resources & Content

1. BJS (British Journal of Surgery), 2023 -- Liver Transplantation as a Treatment for Non-Resectable Locally Advanced Intrahepatic Cholangiocarcinoma Following Neoadjuvant Therapy: Initial Findings from the TESLA Study
2. The ASCO Post, 2026 -- Ablative Radiotherapy May Improve Outcomes for Patients With ‘Supermassive’ Intrahepatic Cholangiocarcinoma
3. Frontiers in Medicine, 2026 -- Case Report: Multimodal treatment for two unresectable intraductal papillary mucinous neoplasms of the bile duct and literature review
4. FDA Approval Summary, 2023 -- Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer
5. ESMO Clinical Practice Guideline, 2024 -- interim update on the management of biliary tract cancer
6. the asco post — Ablative Radiotherapy May Improves Outcomes for Patients With ‘Supermassive’ Intrahepatic Cholangiocarcinoma
7. FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer - PMC
8. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer - PMC